follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Alvogen acquires rights to pain medication with $58M in 2012 sales

By

Back to Top Comments Email Print

News You Can Use

Latest News

    advertisement

    Global generic pharmaceuticals company Alvogen, with its U.S. base in the Pine Brook section of Montville Township, announced today it has acquired U.S. commercialization rights for a controlled-release pain killer from Florham Park-based Shionogi Inc.

    According to the announcement, the nonsteroidal anti-inflammatory Naprelan is manufactured in controlled-release tablets at dosages of 375 mg, 500 mg and 750 mg. The product will be marketed by Almatica Pharma Inc., a subsidiary of Alvogen. In a separate transaction, Alvogen also acquired all rights and interest in the new drug application to the U.S. Food and Drug Administration for Naprelan from Pa.-based Stat-Trade Inc.

    Financial terms of the transaction were not disclosed, but Naprelan had annual U.S. sales of $58 million in 2012, the company said in a statement.

    The company announced Darren Alkins as its new president in October.

    Share This Story On:

    Write to the Editorial Department at editorial@njbiz.com

    advertisement

    Comments


    Be the first to comment.



    Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

    Post Comment
         View Comment Policy

    Advanced search
    Sponsored by
    advertisement
      
      
    advertisement
      
      
    advertisement
    Back to Top